Results came from a phase 1 trial of RP-A501 for treatment of Danon Disease and sent shares up 75% on the Nasdaq to more than $56, a five-year high. The surging stock price indicates the market's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback